Comparative Pharmacology
Head-to-head clinical analysis: RADIOGENIX SYSTEM versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RADIOGENIX SYSTEM versus SETHOTOPE.
RADIOGENIX SYSTEM vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance.
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical